Arena Pharma (ARNA) Posts Q3 Loss of 5c/Share; Revs Miss Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. GOOGL
6. USO
7. STZ
8. CRGY
9. AAPL
10. SPY

Go back to Arena Pharma (ARNA) Posts Q3 Loss of 5c/Share; Revs Miss Expectations

Arena Pharma (ARNA), Eisai Report Significant Phase 2 Data from Lorcaserin in Smoking Cessation

November 3, 2014 6:50 AM EST

Eisai Inc. and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation. The trial demonstrated statistically significant improvement over placebo in reducing the number of patients who smoke after 12 weeks of treatment. The detailed results of the trial are expected to be presented at a future scientific meeting.

Lorcaserin is an investigational product for smoking cessation. The efficacy and safety of lorcaserin for smoking cessation have not been established.

"We are pleased that this proof-of-concept trial... More